United States - English - NLM (National Library of Medicine)

bausch health us, llc - secobarbital sodium (unii: xbp604f6um) (secobarbital - unii:1p7h87in75) - secobarbital sodium 100 mg - seconal sodium is contraindicated in patients who are hypersensitive to barbiturates. it is also contraindicated in patients with a history of manifest or latent porphyria, marked impairment of liver function, or respiratory disease in which dyspnea or obstruction is evident. abuse and addiction are separate and distinct from physical dependence and tolerance. abuse is characterized by misuse of the drug for non-medical purposes, often in combination with other psychoactive substances. physical dependence is a state of adaptation that is manifested by a specific withdrawal syndrome that can be produced by abrupt cessation, rapid dose reduction, decreasing blood level of the drug and/or administration of an antagonist. tolerance is a state of adaptation in which exposure to a drug induces changes that result in a diminution of one or more of the drug's effects over time. tolerance may occur to both the desired and undesired effects of drugs and may develop at different rates for different effects. addiction is

United States - English - NLM (National Library of Medicine)

marathon pharmaceuticals, llc - secobarbital sodium (unii: xbp604f6um) (secobarbital - unii:1p7h87in75) - secobarbital sodium 100 mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

special order - secobarbital sodium - oral capsule - 25mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

special order - secobarbital sodium - oral capsule - 100mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

special order - secobarbital sodium - oral capsule - 50mg

United States - English - NLM (National Library of Medicine)

ranbaxy pharmaceuticals inc. - secobarbital sodium (unii: xbp604f6um) (secobarbital - unii:1p7h87in75) - capsule - 100 mg - a. hypnotic, for the short-term treatment of insomnia, since it appears to lose its effectiveness for sleep induction and sleep maintenance after 2 weeks (see clinical pharmacology). b. preanesthetic seconal sodium is contraindicated in patients who are hypersensitive to barbiturates. it is also contraindicated in patients with a history of manifest or latent porphyria, marked impairment of liver function, or respiratory disease in which dyspnea or obstruction is evident. abuse and addiction are separate and distinct from physical dependence and tolerance. abuse is characterized by misuse of the drug for non-medical purposes, often in combination with other psychoactive substances. physical dependence is a state of adaptation that is manifested by a specific withdrawal syndrome that can be produced by abrupt cessation, rapid dose reduction, decreasing blood level of the drug and/or administration of an antagonist. tolerance is a state of adaptation in which exposure to a drug induces changes that result in a

Ireland - English - HPRA (Health Products Regulatory Authority)

dechra regulatory b.v. - secobarbital sodium; cinchocaine hydrochloride - solution for injection - 400/25 milligram(s)/millilitre - barbiturates in combination with other drugs

Canada - English - Health Canada

pharmascience inc - secobarbital sodium - capsule - 100mg - secobarbital sodium 100mg - barbiturates, plain

Canada - English - Health Canada

novopharm limited - secobarbital sodium - capsule - 100mg - secobarbital sodium 100mg - barbiturates

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

special order - amobarbital sodium; secobarbital sodium - oral capsule - 50mg ; 50mg